News from merck kgaa, darmstadt, germany A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 24, 2019, 11:28 ET Mide Tu Tiroides concientiza a la población latinoamericana sobre el hipotiroidismo y sus síntomas

La campaña digital forma parte de la 11ª Semana Internacional de Concientización sobre la Tiroides, del 25 a 31 de mayo El hipotiroidismo y los...


May 22, 2019, 08:00 ET Experts Discuss Decentralized Manufacturing to Tackle Neglected Tropical Diseases and Promote Universal Health Coverage at World Health Assembly Event

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today hosted a panel discussion on the occasion of the 72nd World Health...


Feb 06, 2019, 09:00 ET Merck KGaA, Darmstadt, Germany to Expand US Biopharmaceutical R&D Facility to Advance Innovative Clinical Pipeline

Merck KGaA, Darmstadt, Germany investing $70 million in U.S. Research & Development Hub Expansion of R&D footprint to accelerate science and...


Jan 24, 2019, 08:00 ET Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic...


Dec 20, 2018, 07:42 ET Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon

Not intended for UK-based media Agreement enables Merck KGaA, Darmstadt, Germany, to maintain an investment in the rapidly advancing oncology field...


Dec 06, 2018, 08:00 ET Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

Not intended for distribution in the U.K. Agreement to screen discovery and early development compounds using artificial intelligence and...


Nov 19, 2018, 08:00 ET Syntropy to Unlock the Value of Scientific Data in Fight to End Cancer

Merck KGaA, Darmstadt, Germany, a leading science and technology company, and software company Palantir Technologies, today announced their intent to ...


Nov 06, 2018, 09:00 ET Embracing Carers™ expands support for caregivers worldwide

Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business in the U.S. and Canada as EMD Serono, today announced the continued...


Oct 22, 2018, 08:45 ET Merck KGaA, Darmstadt, Germany, Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress

Merck KGaA, Darmstadt, Germany, the vibrant science and technology company which operates its healthcare business in the U.S. and Canada as EMD...


Oct 12, 2018, 08:15 ET Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, Evobrutinib in RMS

Merck KGaA, Darmstadt, Germany, the vibrant science and technology company, today announced the 24-week results of the double-blind, randomised,...


Oct 09, 2018, 02:00 ET Merck KGaA, Darmstadt, Germany Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care

ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF β-trap/anti-PD-L1): 1048O, 1463P, 1931P, 757P, 643P, 642P, 661P;...


Jun 11, 2018, 08:30 ET Merck KGaA, Darmstadt, Germany Provides Update on Tepotinib Phase II Results in Advanced Hepatocellular Carcinoma

Not intended for UK-based media Primary endpoints met in two clinical trials for investigational targeted therapy, tepotinib, as a monotherapy in...


Jun 05, 2018, 06:02 ET Brasil aprueba el uso de avelumab para tratar el carcinoma de células de Merkel, es la primera aprobación obtenida en América Latina

La Agencia Nacional de Vigilancia Sanitaria de Brasil (ANVISA) ha aprobado en ese país el fármaco avelumab, inyección genético-recombinante 200mg/mL...


Jun 04, 2018, 08:15 ET Merck KGaA, Darmstadt, Germany Presents Updated Clinical Results for Bifunctional Immunotherapy M7824 at ASCO 2018

ASCO Abstract # M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566, TPS3130; Tepotinib (c-Met kinase inhibitor): 9082, 9016; M2698 (dual p70S6k/Akt...


Jun 03, 2018, 08:30 ET Merck KGaA, Darmstadt, Germany Presents Update on Tepotinib in Advanced Lung Cancer at ASCO 2018

Not intended for UK-based media ASCO Abstract # Tepotinib (c-Met kinase inhibitor): 9082, 9016; M7824 (TGF-ß trap/anti-PD-L1): 3007, 9017, 2566;...


May 02, 2018, 08:00 ET Merck KGaA, Darmstadt, Germany to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ Pharmaceuticals Group

Agreement enables Merck KGaA, Darmstadt, Germany, to further develop abituzumab through a novel risk-sharing collaboration agreement SFJ...


Apr 18, 2018, 08:00 ET Merck KGaA, Darmstadt, Germany, Presents New Osteoarthritis Data at OARSI 2018 World Congress

Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its healthcare business in the U.S. and Canada as EMD Serono, ...


Mar 07, 2018, 09:55 ET Merck KGaA, Darmstadt, Germany, Announces Positive Phase IIB Results for Evobrutinib in Relapsing Multiple Sclerosis

Primary endpoint met for evobrutinib (Bruton's Tyrosine Kinase Inhibitor - BTK) in relapsing multiple sclerosis (MS) First proof of concept for BTK...


Feb 15, 2018, 08:30 ET Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to...


Feb 01, 2018, 01:46 ET Merck KGaA, Darmstadt, Germany certified as one of the Top Employers North America 2018

For the second year in a row, the North American businesses of Merck KGaA, Darmstadt, Germany, a leading science and technology company, have been...


Dec 21, 2017, 12:00 ET FDA Grants Breakthrough Therapy Designation for Avelumab in Combination with INLYTA® in Advanced Renal Cell Carcinoma

Second Breakthrough Therapy Designation for avelumab in hard-to-treat cancer Renal cell carcinoma, the most common form of kidney cancer, has a poor...


Dec 05, 2017, 07:22 ET Merck KGaA, Darmstadt, Germany Announces FDA 510(k) Clearance of Partner Genea Biomedx’s Fertility Benchtop Incubator Geri™

Expanded Fertility Technology portfolio highlights Merck KGaA, Darmstadt, Germany's commitment to improve fertility treatment outcomes for patients U....


Nov 28, 2017, 07:10 ET Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancer

Not intended for UK-based media Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable,...


Nov 17, 2017, 07:01 ET Merck KGaA, Darmstadt, Germany's Massachusetts-based Business Sectors Named 'Top Place to Work' by The Boston Globe

Merck KGaA, Darmstadt, Germany today announced that its Massachusetts-based business sectors, EMD Serono and MilliporeSigma, have been named to The...


Nov 04, 2017, 19:30 ET Merck KGaA, Darmstadt, Germany Presents Late Breaking Clinical Data from Phase II Trial of Sprifermin for Osteoarthritis Disease Modification

Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its healthcare business in the U.S. and Canada as EMD Serono, ...